|
|
|
|
|
Highlights from the 2022 American Urological Association Annual Meeting |
|
|
|
|
|
|
| Panel Discussion: What is the Optimal Multidisciplinary Team in 2022: Drafting for the Future |
| Leonard G. Gomella, MD; Michael S. Cookson, MD, MHA; and Neal D. Shore, MD |
| The 2022 Annual Meeting of the American Urological Association was host to a panel discussion on the significance of multidisciplinary teams in the management of urologic oncology patients and the importance of a collaborative approach to optimizing patient care. This panel discussion was expertly moderated by Dr. Leonard Gomella with Drs. Neal Shore and Michael Cookson as panelists. |
|
|
|
|
|
| Best Prostate Biopsy Techniques in 2022 |
| Daniel Barocas, MD, MPH; Arvin George, MD; Benjamin Ristau, MD; Kristen Scarpato, MD, MPH; and Samir Taneja, MD |
| The 2022 Annual Meeting of the American Urological Association was host to a panel discussion of the best prostate biopsy techniques in 2022. This session was moderated by Dr. Daniel Barocas with Drs. Arvin George, Benjamin Ristau, Kristen Scarpato, and Samir Taneja as the panel speakers. |
|
|
|
|
|
| Battle of the Robots: Which is Superior? Single-Port vs Multi-Port Robotic Prostatectomy |
| Li Ming Su, MD; Jihad Kaouk, MD; and Jeffrey Cadeddu, MD |
| In this plenary session, Dr. Jeffrey Cadeddu, Dr. Jihad Kaouk, and Dr. Li-Ming Su elaborated on the specific advantages and disadvantages of the multiport (MP) and single port (SP) robotic platforms in performing prostatectomies in hopes of delineating one’s superiority over the other. Of note, Dr. Cadeddu and Dr. Kaouk, who were both arguing counterpoints, have experience with both robotic platforms. |
|
|
|
|
|
|
Prostate Cancer: Epidemiology & Natural History I
|
|
| Grade Migration of Prostate Cancer at Diagnosis Following the US Preventive Services Task Force Recommendations on Prostate Cancer Screening |
| Leonardo D. Borregales, MD |
| In a podium presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Leonardo Borregales presented results of an analysis examining grade migration in prostate cancer as a result of changes in guidelines regarding prostate cancer screening. |
|
|
|
|
|
| Prostate Cancer: Detection & Screening II |
| Accuracy and Racial/Ethnic Representation of Prostate Cancer Screening Videos on Youtube and Tiktok |
| Max Abramson, BA |
| Max Abramson presented results of a study assessing the racial/ethnic representation and content accuracy of prostate screening videos on Youtube and Tiktok. Compared to white men, the mortality rate from prostate cancer and the risk of advanced stage disease are higher among Black men and Hispanic men, respectively. |
|
|
|
|
|
|
|
|
|
|
| The Limited Utility of Prostate Health Index in African American Men with a PSA 4-10 |
| Kostantinos Morris |
| Kostantinos Morris presented an assessment of the usage of prostate health index (PHI) in pre-biopsy work-up of African-American men. Based on this data, the current PHI stratification is not useful for African-American men as seen by the elevated PCa detection across all four groups. PHI does not avoid unnecessary biopsies in the high-risk population, even with the proposed cutoff of PHI 23.0. PHI may be a helpful tool in increasing biopsy compliance in high-risk African American men. |
|
|
|
|
|
| Prostate Cancer: Localized: Surgical Therapy I |
| Topographic Description of the Site of Positive mpMRI and Impact on the Risk of Positive Surgical Margins at Robot-Assisted Nerve Sparing Radical Prostatectomy: Implications for Accurate Surgical Approaches |
| Francesco Barletta, MD |
| Francesco Barletta discussed the topographic description of the site of positive multiparametric MRI (mpMRI) and impact on the risk of positive surgical margins at robot-assisted nerve sparing radical prostatectomy. These findings should help surgeons in guiding the optimal extent of the dissection during nerve-sparing robot-assisted radical prostatectomy. |
|
|
|
|
|
| Impact of Disease Status Heterogeneity of the STAMPEDE Trial Arm J Population on Oncological Outcomes in High-Risk Nonmetastatic Prostate Cancer |
| Shingo Hatakeyama, MD |
| Shingo Hatakeyama discussed the impact of disease status heterogeneity of the STAMPEDE trial arm J population on oncological outcomes in high-risk nonmetastatic prostate cancer. There was meaningful heterogeneity of background for outcome in the STAMPEDE trial arm J population. The effect of local therapy on prognosis was significant in patients with non-metastatic-high-risk prostate cancer. |
|
|
|
|
|
| Survival After Radical Prostatectomy Versus Radiation Therapy in Ductal Carcinoma of the Prostate
|
| Francesco Chierigo
|
| Francesco Chierigo discussing survival after radical prostatectomy versus radiation therapy in ductal carcinoma of the prostate. Given the lack of data comparing these two treatment modalities for this aggressive prostate cancer histology, Dr. Chierigo and colleagues compared cancer specific mortality rates between radical prostatectomy versus external beam radiotherapy among these patients.
|
|
|
|
|
|
| Prostate Cancer: Localized: Radiation Therapy |
| Restaging PSMA PET/CT is Associated with Improved Oncological Outcome in Men who Underwent Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer |
| Dennie Meijer, MD
|
| In a moderated poster presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. Meijer presented results of a study examining the clinical implications of restaging prostate-specific membrane antigen (PSMA)-PET/CT at the time of biochemical recurrence following radical prostatectomy.
|
|
|
|
|
|
|
|
|
|
|
| Immediate Radiotherapy versus Observation in Patients with Node-Positive Prostate Cancer after Radical Prostatectomy |
| Boris Gershman, MD |
| Boris Gershman presented on behalf of Dr. Schaufler to discuss the role of immediate radiotherapy in patients with evidence of nodal spread following radical prostatectomy for prostate cancer. The optimal management of these patients who are found to have node positive disease (pN1) at the time of radical prostatectomy is uncertain. |
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) I |
| Long-term Safety of Darolutamide Among Patients With Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy
|
| Robert Jones, MD, Ph.D.
|
| Jones presented on the long-term safety of darolutamide among patients with metastatic castration-resistant Prostate Cancer (mCRPC). The authors concluded that, in this small group of patients with mCRPC from the phase 1 ARAFOR study, long-term treatment with darolutamide beyond 4 years was generally well tolerated and no new safety signals were observed.
|
|
|
|
|
|
| Comparative Out-of-Pocket Costs of Treatment Options in Privately Insured Patients with Advanced Prostate Cancer |
| Daniel Joyce, MD |
| Daniel Joyce presented data examining out-of-pocket costs for privately insured patients receiving treatment for advanced prostate cancer. While financial toxicity is a significant burden for many patients with cancer, this is relatively understudied in patients with advanced prostate cancer. |
|
|
|
|
|
| Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study |
| Neal D. Shore, MD, FACS |
| Neal Shore presented a detailed safety analysis of the oral LHRH antagonist relugolix, based on data from the HERO trial. This trial, which enrolled men with advanced prostate cancer, demonstrated that relugolix, a highly selective nonpeptide oral GnRH antagonist, was well tolerated, with hot flash and fatigue as the most frequently reported adverse events (AE) for men in both relugolix and leuprolide groups. |
|
|
|
|
|
| Practice Patterns in Management of Hormone Sensitive Metastatic and Castrate-Resistant Non-Metastatic Prostate Cancer |
| Daniel Joyce, MD |
| Daniel Joyce presented an analysis examining practice patterns in the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and with non-metastatic castrate-resistant prostate cancer (nmCRPC). |
|
|
|
|
|
|
